A correction notice in JAMA Network Open updates an introductory sentence in the Introduction of the Original Investigation “Erythropoiesis-Stimulating Agents and Development of Cancer Among Patients Receiving Dialysis.” The revised sentence emphasizes that mechanistic studies show ESAs can activate erythropoietin receptors, while clinical evidence for ESA-associated increases in angiogenesis or tumor growth is controversial and based on low-quality literature. It cites references 8–10 (Elliot and Sinclair, Diskin et al, Cao) and notes that large-scale cancer outcome data in kidney failure populations are sparse and inconsistent.
The correction indicates that the article has been corrected. The item provides no data on study methods, results, or numerical outcomes beyond the stated context of evidence quality and inconsistency.
If precise wording or reference details beyond the described revision are needed, consult the journal’s correction notice for the exact phrasing and reference formatting. The uncertainty noted centers on the quality and conclusiveness of existing evidence rather than new study findings.
JAMA Network Open published a clinical update in Research Highlights on 02 Apr 2026.
The item focuses on Wording Change in Introduction.
Review the original article for the full source wording and details.